Pexidartinib
Sign in to save this workspacePrimary targets: FMS · FDA status: FDA Approved
Selectivity scorecard
KISS
99.49
Gini
0.631
CATDS
0.029
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Pexidartinib. Strongest target: FMS at 97.5% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | FMS | 97.5% | 2.5% |
| 2 | C_KIT | 95.2% | 4.8% |
| 3 | AURORA_B | 80.3% | 19.7% |
| 4 | FLT3 | 79.3% | 20.7% |
| 5 | DDR2 | 63.2% | 36.8% |
| 6 | RET | 62.9% | 37.1% |
| 7 | PDGFRB | 62.4% | 37.6% |
| 8 | DDR1 | 60.0% | 40.0% |
| 9 | LCK | 51.9% | 48.1% |
| 10 | TRKC | 46.5% | 53.5% |
| 11 | AURORA_A | 43.9% | 56.1% |
| 12 | LRRK2 | 40.4% | 59.6% |
| 13 | FGFR2 | 39.9% | 60.1% |
| 14 | TRKB | 36.7% | 63.3% |
| 15 | RIPK4 | 35.5% | 64.5% |
| 16 | MUSK | 35.1% | 64.9% |
| 17 | LKB1 | 34.4% | 65.6% |
| 18 | MLK2_MAP3K10 | 34.3% | 65.7% |
| 19 | MAK | 31.7% | 68.3% |
| 20 | FGFR1 | 30.2% | 69.8% |
Selectivity landscape
Where Pexidartinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Pexidartinib.
Annotations
Sign in to read and post annotations.
Loading…